

-Remarks-

Restriction requirement.

The Examiner has required restriction of the claims of the instant application to one of two groups:

Group I: Claims 1 - 3 and 6 - 11, drawn to a composition comprising a histamine H1 antagonist and a H4 antagonist.

Group II: Claims 4, 5, 12 and 13, drawn to a method of treating a disease or disorder in a mammal using the compositions of Group I.

Applicants hereby elect Group I, without traverse.

Amendments:

Entry of the above amendments is respectfully requested. Claims 3, 6 and 9 were amended to clarify the claim language. Claims 2 - 5, 7 and 10 - 13 were canceled either to conform the claims to the Group elected in response to the restriction requirement or to remove nonstatutory claims from the application. All amendments and cancelations were made without waiver or prejudice. Applicants reserve the right to file divisional or continuation applications directed to the nonelected or other canceled subject matter of this invention.


-Conclusion-

Applicants, having responded to all points and concerns raised by the Examiner, believe this application to be in condition for allowance. An early and favorable action is respectfully requested.

Dated: March 25, 2003

Pfizer Inc.  
Patent Department  
Eastern Point Road  
Groton, CT 06340  
(860) 441-5910

Respectfully submitted,

  
Robert T. Ronau  
Attorney for Applicants  
Reg. No. 36,257